Skip to Main Content

KMAP BULLETIN: Preferred Drug List Update February 2026

Date: 02/09/26

KMAP GENERAL BULLETIN 26010 (PDF)

Effective with dates of service on or after February 1, 2026, the following medications will be Non-Preferred:

  • Desloratadine (Oral Solution)
  • Arbli™ (lostartan potassium 10 mg/mL)
  • Vyscoxa™ (celecoxib)
  • Imuldosa® (ustekinumab-srlf)- (Labeler 51407)
  • Chlorzoxazone 250mg
  • Kirsty™ (insulin aspart-xjhz)
  • Coxanto™ (Oxaprozin)
  • Relafen DS® (Nabumetone) 1000mg
  • Javadin™ (clonidine)


Effective with dates of service on or after February 1, 2026, the  following medications will be Preferred:

  • Imuldosa (ustekinumab-srlf)- (Labeler 69448)


Note: The effective date of the policy is February 1, 2026. The implementation of State policy by the KanCare Managed Care Organizations (MCOs) may vary from the date noted in the Kansas Medical Assistance Program (KMAP) bulletins. The KanCare Open Claims Resolution Log on the KMAP Bulletins page documents the MCO system status for policy implementation and any associated reprocessing completion dates once the policy is implemented.